| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1002253503 |
| P356 | DOI | 10.1038/SJ.JID.5700117 |
| P698 | PubMed publication ID | 16439972 |
| P5875 | ResearchGate publication ID | 7333631 |
| P2093 | author name string | Daisuke Sawamura | |
| Hiroshi Shimizu | |||
| Kaori Sakai | |||
| Maki Goto | |||
| Masashi Akiyama | |||
| Kei Ito | |||
| Akihiko Shibaki | |||
| Wataru Nishie | |||
| Masataka Abe | |||
| P2860 | cites work | Serial cultivation of strains of human epidermal keratinocytes: the formation of keratinizing colonies from single cells | Q29614425 |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | gene therapy | Q213901 |
| keratinocyte | Q1473931 | ||
| P304 | page(s) | 766-772 | |
| P577 | publication date | 2006-04-01 | |
| P1433 | published in | Journal of Investigative Dermatology | Q3186921 |
| P1476 | title | Fibroblasts show more potential as target cells than keratinocytes in COL7A1 gene therapy of dystrophic epidermolysis bullosa | |
| P478 | volume | 126 |
| Q81770605 | Allogeneic cell therapy for epidermolysis bullosa |
| Q45956637 | Amlexanox Enhances Premature Termination Codon Read-Through in COL7A1 and Expression of Full Length Type VII Collagen: Potential Therapy for Recessive Dystrophic Epidermolysis Bullosa. |
| Q37109093 | An approach to achieve long-term expression in skin gene therapy |
| Q38772377 | Analysis of the functional consequences of targeted exon deletion in COL7A1 reveals prospects for dystrophic epidermolysis bullosa therapy |
| Q36855693 | Bone marrow cell transfer into fetal circulation can ameliorate genetic skin diseases by providing fibroblasts to the skin and inducing immune tolerance |
| Q51813890 | COL7A1 mutation G2037E causes epidermal retention of type VII collagen. |
| Q50897287 | CRISPR/Cas9-based genetic correction for recessive dystrophic epidermolysis bullosa. |
| Q33653689 | Cell therapy in dermatology. |
| Q45871193 | Correction of dog dystrophic epidermolysis bullosa by transplantation of genetically modified epidermal autografts |
| Q28084871 | Dystrophic epidermolysis bullosa: a review |
| Q41172136 | Epidermal and dermal integration into sphere-templated porous poly(2-hydroxyethyl methacrylate) implants in mice |
| Q36801662 | Epidermolysis bullosa acquisita associated with psoriasis vulgaris |
| Q81770612 | Epidermolysis bullosa: prospects for cell-based therapies |
| Q36326838 | Gene editing toward the use of autologous therapies in recessive dystrophic epidermolysis bullosa |
| Q26994703 | Gene therapy for skin diseases |
| Q38150897 | Gene therapy: pursuing restoration of dermal adhesion in recessive dystrophic epidermolysis bullosa |
| Q53770761 | Genetically corrected iPSCs as cell therapy for recessive dystrophic epidermolysis bullosa. |
| Q37462643 | Keratinocyte-/fibroblast-targeted rescue of Col7a1-disrupted mice and generation of an exact dystrophic epidermolysis bullosa model using a human COL7A1 mutation |
| Q36595683 | Lentiviral Engineered Fibroblasts Expressing Codon-Optimized COL7A1 Restore Anchoring Fibrils in RDEB. |
| Q53143040 | Management of severe epidermolysis bullosa by haematopoietic transplant: principles, perspectives and pitfalls. |
| Q33713926 | Mechanisms of fibroblast cell therapy for dystrophic epidermolysis bullosa: high stability of collagen VII favors long-term skin integrity |
| Q53487278 | Potential of fibroblast cell therapy for recessive dystrophic epidermolysis bullosa. |
| Q37499984 | Progress in heritable skin diseases: translational implications of mutation analysis and prospects of molecular therapies*. |
| Q38510204 | Recessive dystrophic epidermolysis bullosa: a review of disease pathogenesis and update on future therapies. |
| Q43042273 | Remodeling of the dermal-epidermal junction in bilayered skin constructs after silencing the expression of the p.R2622Q and p.G2623C collagen VII mutants |
| Q84468361 | Revertant mosaicism due to a second-site mutation in COL7A1 in a patient with recessive dystrophic epidermolysis bullosa |
| Q92547553 | Safety and early efficacy outcomes for lentiviral fibroblast gene therapy in recessive dystrophic epidermolysis bullosa |
| Q36915141 | TALEN-based gene correction for epidermolysis bullosa. |
| Q36834374 | The role of fibroblasts in tissue engineering and regeneration. |
| Q45875820 | The skin as a biofactory for systemic secretion of erythropoietin: potential of genetically modified keratinocytes and fibroblasts |
| Q37341382 | Transgene-specific host responses in cutaneous gene therapy: the role of cells expressing the transgene |
Search more.